NCT06946732 Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism
| NCT ID | NCT06946732 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Pulmonary Embolism (PE) |
| Study Type | INTERVENTIONAL |
| Enrollment | 127 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 127 participants in total. It began in 2025-04-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The registry is to evaluate the safety and feasibility of catheter-directed aspiration for patients with high-risk and intermediate-high-risk pulmonary embolism using Acostream.
Eligibility Criteria
Inclusion Criteria: * 18≤Age≤85 * Clinical symptoms and presentation consistent with pulmonary embolism (PE). * PE symptoms duration ≤ 14 days. * High risk PE patients with absolute contraindications to systemic thrombolysis or its failure (refractory circulatory collapse) not eligible for surgical embolectomy. * Intermediate-high risk PE patients with right ventricle dysfunction (right ventricle/ left ventricle \>0.9) confirmed by computed tomography pulmonary angiography or transthoracic echocardiography. Exclusion Criteria: * Pregnancy. * Refusal to sign the informed consent form. * Presence of intracardiac thrombus. * Presence of chronic left heart failure with an ejection fraction lower than 30% Diagnosed thrombophilia. * History of severe or chronic pulmonary hypertension. * Serum creatinine level higher than 1.8 mg/dl. * Known serious and uncontrolled sensitivity to radiographic agents.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06946732 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Pulmonary Embolism (PE). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06946732 currently recruiting?
Yes, NCT06946732 is actively recruiting participants. Contact the research team at niqihong1989@163.com for enrollment information.
Where is the NCT06946732 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06946732 clinical trial?
NCT06946732 is sponsored by RenJi Hospital. The trial plans to enroll 127 participants.